RxDoctor Payments Data

Mona Camacci, MD

Ophthalmology · Charleston, SCNPI 1669900114

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $15,862 of the $26,210 with a category attached, or 60.5%. Astellas Pharma US Inc accounts for 69.5% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $17,098, more than ten times the $141 reported in 2021. Among ophthalmology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$26,210in general payments, 2019–2025

Across 78 payments — averaging $336.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$18K
  • Genentech USA, Inc.$3K
  • Ocular Therapeutix, Inc.$3K
  • Apellis Pharmaceuticals, Inc.$2K
  • Alimera Sciences, Inc.$369
  • Regeneron Healthcare Solutions, Inc.$209
  • plus $446 from 7 others
$507,943in research payments, 2019–2025

Across 56 payments — averaging $9070.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ocular Therapeutix, Inc.$475K
  • AbbVie$17K
  • Janssen Research & Development, LLC$16K

What the payments were for

  • Consulting fees$6,47925%
  • Speaking & faculty fees$15,86261%
  • Travel & lodging$1,0594%
  • Food & beverage$2,81011%

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,210 in reported general payments places this provider in the 90th percentile of 293 ophthalmology providers in South Carolina.

See all ophthalmology providers in South Carolina

Medicare billing

Part B allowed, 2024
$4,777,878
Medicare patients
1,096
Services billed
29,951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate84$4,566
Atropine Sulfate81$2,543
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha172$2,102
Timolol Maleate20$1,781
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat81$1,195
Difluprednate11$964
Brimonidine Tartrate68$660
Ketorolac Tromethamine32$646
Acetazolamide ErAcetazolamide18$578
MoxifloxacinMoxifloxacin Hcl26$383
Acetazolamide11$341
Latanoprost21$260
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim13$37

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →